• SPX
  • $5,994.53
  • -0.11 %
  • -$6.82
  • DJI
  • $44,062.25
  • -0.52 %
  • -$230.89
  • N225
  • $39,376.09
  • -0.4 %
  • -$157.23
  • FTSE
  • $8,025.77
  • -1.22 %
  • -$99.42
  • IXIC
  • $19,294.79
  • -0.02 %
  • -$3.98
Moleculin Biotech, Inc. (MBRX) Stock Price, News & Analysis

Moleculin Biotech, Inc. (MBRX) Stock Price, News & Analysis

Currency in USD Disclaimer

$2.68

$0.18

(7.2%)

Day's range
$2.54
Day's range
$2.71
50-day range
$2.29
Day's range
$3.09
  • Country: US
  • ISIN: US60855D2009
52 wk range
$0.4
Day's range
$6.24


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -12.54
  • Piotroski Score 4.00
  • Grade Buy
  • Symbol (MBRX)
  • Company Moleculin Biotech, Inc.
  • Price $2.68
  • Changes Percentage (7.2%)
  • Change $0.18
  • Day Low $2.54
  • Day High $2.71
  • Year High $6.24

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/20/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Neutral
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$13.04
  • Trailing P/E Ratio -0.33
  • Forward P/E Ratio -0.33
  • P/E Growth -0.33
  • Net Income $-29,769,000

Income Statement

Quarterly

Annual

Latest News of MBRX

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.